Cytori Therapeutics Inc (NASDAQ:CYTX) presented preclinical data at the Annual Meeting of the American Burn Association (ABA) in Las Vegas showing the potential of Cytori’s DCCT-10 cell therapy for hypertrophic scarring (HTS), a common consequence of burn injury.

In this research Cytori scientists developed and applied a preclinical model of HTS in two treatment studies. In the first, DCCT-10 was applied to deep partial thickness skin wounds immediately following injury. Wounds were then followed for six months to allow for the development of HTS. Results demonstrate that delivery of DCCT-10 immediately after injury led to a 60% increase in the number of anchoring structures called ‘rete ridges’ or ‘rete pegs’ within the skin (p<0.001) of treated wounds compared to the control. Rete ridges, which help to anchor the epidermis to the dermis, are absent or substantially reduced in scar tissue which is one reason that scar epidermis is often more fragile than that of normal skin. The six month data also showed a 15% decrease in skin hardness in DCCT-10-treated wounds (p=0.067). The second study, which is still ongoing, used the same model to assess use of DCCT-10 delivered six months after deep partial thickness injury in which a hypertrophic scar had already formed. Preliminary data from this study presented today show a 20-40% decrease in skin hardness at 1 and 2 months post-treatment.

While DDC-10 treatment appeared to modulate skin pliability and hardness in both studies, no effect was observed on scar pigmentation or erythema.

“These data suggest the potential for DCCT-10 therapy to mitigate scarring following deep partial thickness skin injury,” said Dr. Marc Hedrick, President and CEO of Cytori. “When combined with earlier work on the use of DCCT-10 following thermal burn injury, these findings suggest a potentially broad utility for this product in burn and wound clinics. We are encouraged by this research and look forward to completing these studies and, in a continuation of our work with BARDA, initiating a clinical trial of DCCT-10 therapy in burn patients within the next year.” (Original Source)

Shares of Cytori are up nearly 8% to $0.26 in pre-market trading. CYTX has a 1-year high of $0.78 and a 1-year low of $0.13. The stock’s 50-day moving average is $0.25 and its 200-day moving average is $0.25.

On the ratings front, Cytori has been the subject of a number of recent research reports. In a report issued on March 28, Maxim Group analyst Jason Kolbert reiterated a Buy rating on CYTX, with a price target of $5, which implies an upside of 1983.3% from current levels. Separately, on March 24, Roth Capital’s Joseph Pantginis maintained a Buy rating on the stock and has a price target of $1.50.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Joseph Pantginis have a total average return of -13.6% and -2.6% respectively. Kolbert has a success rate of 31.0% and is ranked #3823 out of 3827 analysts, while Pantginis has a success rate of 35.9% and is ranked #3570